H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Acadia Pharmaceuticals to $28 from $25 and keeps a Buy rating on the shares following FDA approval of trofinetide with a "clean" label. A broad and clean label provides more upside than was previously valued into Daybue by the Street, positively impacting Daybue launch dynamics, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ACAD:
- Acadia Pharmaceuticals announces FDA approval of DAYBUE for Rett syndrome
- Acadia Pharmaceuticals price target raised to $24 from $20 at Canaccord
- This ETF Has 67% Upside Potential, According to Analysts
- Acadia Pharmaceuticals price target raised to $27 from $19 at RBC Capital
- Acadia Pharmaceuticals price target raised to $19 from $15 at Mizuho
